File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy

TitleIncreased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy
Authors
Issue Date2008
PublisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/
Citation
Nephrology Dialysis Transplantation, 2008, v. 23 n. 3, p. 927-933 How to Cite?
AbstractBackground. Advanced glycation end products (AGEs) play an important role in the pathogenesis of diabetic complications. Recent data suggest that AGEs may also interfere with the function of HDL and the reverse cholesterol transport pathway. We have investigated whether serum AGE level is associated with impairment in the antioxidative capacity of HDL and in the ability of serum to induce cholesterol efflux in type 2 diabetic patients with and without nephropathy. Methods. A total of 167 controls and 264 diabetic patients was recruited. The ability of serum to induce cellular cholesterol efflux and the capacity of HDL to inhibit LDL oxidation ex vivo was determined. Serum AGEs were assayed by competitive ELISA using a polyclonal rabbit antisera raised against AGE-RNase. Results. Diabetic subjects were subdivided into three groups (normoalbuminuria, microalbuminuria and proteinuria). Serum AGEs were significantly increased in diabetic patients with microalbuminuria or proteinuria (P < 0.001). Cholesterol efflux was significantly decreased in all three groups of diabetic patients compared to controls (P < 0.001) whereas the antioxidative capacity of HDL was significantly impaired in patients with microalbuminuria or proteinuria (P < 0.01). No relationship between serum AGEs and cholesterol efflux was found. However, serum AGE concentration was significantly associated with the antioxidative capacity of HDL and this was partly due to the adverse effect of AGEs on paraoxonase-1 activity. Conclusion. In type 2 diabetic patients with incipient or overt nephropathy, increased serum concentration of AGEs was associated with impairment in the antioxidative capacity of HDL. Cholesterol efflux to serum was also reduced but was not related to serum AGEs. © The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163163
ISSN
2015 Impact Factor: 4.085
2015 SCImago Journal Rankings: 1.780
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZhou, Hen_US
dc.contributor.authorTan, KCBen_US
dc.contributor.authorShiu, SWMen_US
dc.contributor.authorWong, Yen_US
dc.date.accessioned2012-09-05T05:28:21Z-
dc.date.available2012-09-05T05:28:21Z-
dc.date.issued2008en_US
dc.identifier.citationNephrology Dialysis Transplantation, 2008, v. 23 n. 3, p. 927-933en_US
dc.identifier.issn0931-0509en_US
dc.identifier.urihttp://hdl.handle.net/10722/163163-
dc.description.abstractBackground. Advanced glycation end products (AGEs) play an important role in the pathogenesis of diabetic complications. Recent data suggest that AGEs may also interfere with the function of HDL and the reverse cholesterol transport pathway. We have investigated whether serum AGE level is associated with impairment in the antioxidative capacity of HDL and in the ability of serum to induce cholesterol efflux in type 2 diabetic patients with and without nephropathy. Methods. A total of 167 controls and 264 diabetic patients was recruited. The ability of serum to induce cellular cholesterol efflux and the capacity of HDL to inhibit LDL oxidation ex vivo was determined. Serum AGEs were assayed by competitive ELISA using a polyclonal rabbit antisera raised against AGE-RNase. Results. Diabetic subjects were subdivided into three groups (normoalbuminuria, microalbuminuria and proteinuria). Serum AGEs were significantly increased in diabetic patients with microalbuminuria or proteinuria (P < 0.001). Cholesterol efflux was significantly decreased in all three groups of diabetic patients compared to controls (P < 0.001) whereas the antioxidative capacity of HDL was significantly impaired in patients with microalbuminuria or proteinuria (P < 0.01). No relationship between serum AGEs and cholesterol efflux was found. However, serum AGE concentration was significantly associated with the antioxidative capacity of HDL and this was partly due to the adverse effect of AGEs on paraoxonase-1 activity. Conclusion. In type 2 diabetic patients with incipient or overt nephropathy, increased serum concentration of AGEs was associated with impairment in the antioxidative capacity of HDL. Cholesterol efflux to serum was also reduced but was not related to serum AGEs. © The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/en_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.subject.meshAdulten_US
dc.subject.meshAntioxidants - Metabolismen_US
dc.subject.meshAryldialkylphosphatase - Metabolismen_US
dc.subject.meshCase-Control Studiesen_US
dc.subject.meshCholesterol, Hdl - Metabolismen_US
dc.subject.meshCholesterol, Ldl - Metabolismen_US
dc.subject.meshDiabetes Mellitus, Type 2 - Metabolismen_US
dc.subject.meshDiabetic Nephropathies - Metabolismen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlycosylation End Products, Advanced - Blooden_US
dc.subject.meshHumansen_US
dc.subject.meshLinear Modelsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.titleIncreased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathyen_US
dc.typeArticleen_US
dc.identifier.emailTan, KCB:kcbtan@hku.hken_US
dc.identifier.authorityTan, KCB=rp00402en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/ndt/gfm631en_US
dc.identifier.pmid18065800-
dc.identifier.scopuseid_2-s2.0-42449126292en_US
dc.identifier.hkuros145701-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-42449126292&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume23en_US
dc.identifier.issue3en_US
dc.identifier.spage927en_US
dc.identifier.epage933en_US
dc.identifier.isiWOS:000253858300023-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridZhou, H=24077909100en_US
dc.identifier.scopusauthoridTan, KCB=8082703100en_US
dc.identifier.scopusauthoridShiu, SWM=7005550652en_US
dc.identifier.scopusauthoridWong, Y=24073787400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats